JPWO2020157692A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020157692A5 JPWO2020157692A5 JP2021544518A JP2021544518A JPWO2020157692A5 JP WO2020157692 A5 JPWO2020157692 A5 JP WO2020157692A5 JP 2021544518 A JP2021544518 A JP 2021544518A JP 2021544518 A JP2021544518 A JP 2021544518A JP WO2020157692 A5 JPWO2020157692 A5 JP WO2020157692A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- composition
- compound
- hiv infection
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000003839 salts Chemical class 0.000 claims description 13
- 239000011780 sodium chloride Substances 0.000 claims description 13
- 150000001875 compounds Chemical class 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 10
- 208000005721 HIV Infections Diseases 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 201000001820 human immunodeficiency virus infectious disease Diseases 0.000 claims description 8
- -1 victegravir Chemical compound 0.000 claims description 7
- 229940079593 drugs Drugs 0.000 claims description 5
- JTEGQNOMFQHVDC-NKWVEPMBSA-N 4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-1,2-dihydropyrimidin-2-one Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 claims description 4
- WCWSTNLSLKSJPK-LKFCYVNXSA-N Cabotegravir Chemical compound C([C@H]1OC[C@@H](N1C(=O)C1=C(O)C2=O)C)N1C=C2C(=O)NCC1=CC=C(F)C=C1F WCWSTNLSLKSJPK-LKFCYVNXSA-N 0.000 claims description 4
- 229950005928 Cabotegravir Drugs 0.000 claims description 4
- RHWKPHLQXYSBKR-BMIGLBTASA-N Dolutegravir Chemical compound C([C@@H]1OCC[C@H](N1C(=O)C1=C(O)C2=O)C)N1C=C2C(=O)NCC1=CC=C(F)C=C1F RHWKPHLQXYSBKR-BMIGLBTASA-N 0.000 claims description 4
- SWMDAPWAQQTBOG-UHFFFAOYSA-N Fostemsavir Chemical compound C1=2N(COP(O)(O)=O)C=C(C(=O)C(=O)N3CCN(CC3)C(=O)C=3C=CC=CC=3)C=2C(OC)=CN=C1N1C=NC(C)=N1 SWMDAPWAQQTBOG-UHFFFAOYSA-N 0.000 claims description 4
- 229950010812 Fostemsavir Drugs 0.000 claims description 4
- 229960001627 Lamivudine Drugs 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 229960002542 dolutegravir Drugs 0.000 claims description 4
- 238000010255 intramuscular injection Methods 0.000 claims description 4
- 239000007927 intramuscular injection Substances 0.000 claims description 4
- 238000010254 subcutaneous injection Methods 0.000 claims description 4
- 239000007929 subcutaneous injection Substances 0.000 claims description 4
- ZIAOVIPSKUPPQW-UHFFFAOYSA-N 3-chloro-5-[1-[(4-methyl-5-oxo-1H-1,2,4-triazol-3-yl)methyl]-2-oxo-4-(trifluoromethyl)pyridin-3-yl]oxybenzonitrile Chemical compound N1C(=O)N(C)C(CN2C(C(OC=3C=C(C=C(Cl)C=3)C#N)=C(C=C2)C(F)(F)F)=O)=N1 ZIAOVIPSKUPPQW-UHFFFAOYSA-N 0.000 claims description 2
- AXRYRYVKAWYZBR-GASGPIRDSA-N Atazanavir Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)[C@@H](O)CN(CC=1C=CC(=CC=1)C=1N=CC=CC=1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C1=CC=CC=C1 AXRYRYVKAWYZBR-GASGPIRDSA-N 0.000 claims description 2
- 229950003141 Doravirine Drugs 0.000 claims description 2
- GSNHKUDZZFZSJB-QYOOZWMWSA-N Maraviroc Chemical compound CC(C)C1=NN=C(C)N1[C@@H]1C[C@H](N2CC[C@H](NC(=O)C3CCC(F)(F)CC3)C=3C=CC=CC=3)CC[C@H]2C1 GSNHKUDZZFZSJB-QYOOZWMWSA-N 0.000 claims description 2
- 229960004946 Tenofovir Alafenamide Drugs 0.000 claims description 2
- 229960003277 atazanavir Drugs 0.000 claims description 2
- 229960005107 darunavir Drugs 0.000 claims description 2
- CJBJHOAVZSMMDJ-HEXNFIEUSA-N darunavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1[C@@H]2CCO[C@@H]2OC1)C1=CC=CC=C1 CJBJHOAVZSMMDJ-HEXNFIEUSA-N 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 229960004710 maraviroc Drugs 0.000 claims description 2
- 239000000546 pharmaceutic aid Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- LDEKQSIMHVQZJK-CAQYMETFSA-N propan-2-yl (2S)-2-[[[(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethyl-phenoxyphosphoryl]amino]propanoate Chemical compound O([P@@](=O)(CO[C@H](C)CN1C2=NC=NC(N)=C2N=C1)N[C@@H](C)C(=O)OC(C)C)C1=CC=CC=C1 LDEKQSIMHVQZJK-CAQYMETFSA-N 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 102000009666 Cytochrome P-450 CYP2B6 Human genes 0.000 description 4
- 108010020070 Cytochrome P-450 CYP2B6 Proteins 0.000 description 4
- XPOQHMRABVBWPR-ZDUSSCGKSA-N Efavirenz Chemical class C([C@]1(C2=CC(Cl)=CC=C2NC(=O)O1)C(F)(F)F)#CC1CC1 XPOQHMRABVBWPR-ZDUSSCGKSA-N 0.000 description 3
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 description 2
- 229960003804 efavirenz Drugs 0.000 description 2
- SOLUWJRYJLAZCX-LYOVBCGYSA-N Bictegravir Chemical compound C([C@H]1O[C@@H]2CC[C@@H](C2)N1C(=O)C1=C(C2=O)O)N1C=C2C(=O)NCC1=C(F)C=C(F)C=C1F SOLUWJRYJLAZCX-LYOVBCGYSA-N 0.000 description 1
- 229950004159 Bictegravir Drugs 0.000 description 1
- 230000037250 Clearance Effects 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000035512 clearance Effects 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000019525 primary metabolic process Effects 0.000 description 1
- 229930010796 primary metabolites Natural products 0.000 description 1
- 230000024053 secondary metabolic process Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962799800P | 2019-02-01 | 2019-02-01 | |
| US62/799,800 | 2019-02-01 | ||
| PCT/IB2020/050743 WO2020157692A1 (en) | 2019-02-01 | 2020-01-30 | Inhibitors of human immunodeficiency virus replication |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022523726A JP2022523726A (ja) | 2022-04-26 |
| JPWO2020157692A5 true JPWO2020157692A5 (fi) | 2023-01-26 |
Family
ID=69528890
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021544518A Pending JP2022523726A (ja) | 2019-02-01 | 2020-01-30 | ヒト免疫不全ウイルス複製の阻害剤 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20220105096A1 (fi) |
| EP (1) | EP3917930B1 (fi) |
| JP (1) | JP2022523726A (fi) |
| AR (1) | AR117920A1 (fi) |
| ES (1) | ES2941240T3 (fi) |
| PT (1) | PT3917930T (fi) |
| TW (1) | TW202045502A (fi) |
| UY (1) | UY38559A (fi) |
| WO (1) | WO2020157692A1 (fi) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7398448B2 (ja) | 2018-10-24 | 2023-12-14 | ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド | ヒト免疫不全ウイルス複製の阻害剤 |
| US20210323967A1 (en) * | 2019-06-19 | 2021-10-21 | Viiv Healthcare Uk (No. 5) Limited | Pyrido[2,3-d]pyrimidine derivatives as inhibitors of human immunodeficiency virus replication |
| WO2021107066A1 (ja) | 2019-11-28 | 2021-06-03 | 塩野義製薬株式会社 | インテグラーゼ阻害剤及び抗ｈｉｖ薬を組み合わせることを特徴とするｈｉｖ感染症の予防及び治療用医薬 |
| CA3164528A1 (en) * | 2019-12-09 | 2021-06-17 | Viiv Healthcare Company | Pharmaceutical compositions comprising cabotegravir |
| CN115551858A (zh) * | 2020-03-06 | 2022-12-30 | Viiv保健英国第五有限公司 | 人类免疫缺陷病毒复制的抑制剂 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102464654B (zh) | 2010-11-12 | 2016-01-13 | 上海泓博智源医药技术有限公司 | 抗病毒化合物 |
| AU2012278976B2 (en) | 2011-07-06 | 2017-05-11 | Gilead Sciences, Inc. | Compounds for the treatment of HIV |
| CN102863512B (zh) | 2011-07-07 | 2016-04-20 | 上海泓博智源医药技术有限公司 | 抗病毒化合物 |
| ES2614053T3 (es) | 2013-01-09 | 2017-05-29 | Gilead Sciences, Inc. | Heteroarilos de 5 miembros y su uso como antivirales |
| TW201443037A (zh) | 2013-01-09 | 2014-11-16 | Gilead Sciences Inc | 治療用化合物 |
| NZ727792A (en) | 2013-01-09 | 2018-04-27 | Gilead Sciences Inc | Therapeutic compounds |
| TWI694071B (zh) | 2013-03-01 | 2020-05-21 | 美商基利科學股份有限公司 | 治療反轉錄病毒科(Retroviridae)病毒感染之治療性化合物 |
| CN106458940A (zh) | 2013-10-24 | 2017-02-22 | 百时美施贵宝公司 | 人类免疫缺陷病毒复制的抑制剂 |
| US10202353B2 (en) | 2014-02-28 | 2019-02-12 | Gilead Sciences, Inc. | Therapeutic compounds |
| WO2015130966A1 (en) | 2014-02-28 | 2015-09-03 | Gilead Sciences, Inc. | Antiviral agents |
| AU2015308907B2 (en) | 2014-08-29 | 2018-10-18 | Gilead Sciences, Inc. | Antiretroviral agents |
| WO2016040084A1 (en) | 2014-09-09 | 2016-03-17 | Bristol-Myers Squibb Company | Inhibitors of human immunodeficiency virus replication |
| BR112017022544A2 (pt) | 2015-04-23 | 2018-07-10 | Viiv Healthcare Uk No 5 Ltd | ?composto, composição, e, método para tratamento de infecção por hiv?. |
| AR104389A1 (es) | 2015-04-23 | 2017-07-19 | Bristol Myers Squibb Co | Inhibidores de la replicación del virus de inmunodeficiencia humana |
| UY37367A (es) | 2016-08-19 | 2018-03-23 | Gilead Sciences Inc | Nuevos compuestos para uso en el tratamiento de una infección viral y composiciones de los mismos |
| UY37710A (es) | 2017-05-02 | 2018-11-30 | Viiv Healthcare Uk No 5 Ltd | Inhibidores de la replicación del virus de la inmunodeficiencia humana |
| TW202024061A (zh) | 2017-08-17 | 2020-07-01 | 美商基利科學股份有限公司 | Hiv蛋白質膜抑制劑之固體形式 |
| AR112412A1 (es) | 2017-08-17 | 2019-10-23 | Gilead Sciences Inc | Formas de sal de colina de un inhibidor de la cápside del vih |
| EP3752495B1 (en) | 2018-02-15 | 2023-07-19 | Gilead Sciences, Inc. | Pyridine derivatives and their use for treating hiv infection |
| AR114631A1 (es) | 2018-02-16 | 2020-09-30 | Gilead Sciences Inc | Métodos e intermedios para preparar compuestos de piridina |
| WO2019198024A1 (en) | 2018-04-11 | 2019-10-17 | VIIV Healthcare UK (No.5) Limited | 4-oxo-3,4-dihydroquinazoline compounds as inhibitors of human immunodeficiency virus replication |
-
2020
- 2020-01-29 UY UY0001038559A patent/UY38559A/es unknown
- 2020-01-30 AR ARP200100242A patent/AR117920A1/es unknown
- 2020-01-30 PT PT207045964T patent/PT3917930T/pt unknown
- 2020-01-30 US US17/425,796 patent/US20220105096A1/en active Pending
- 2020-01-30 EP EP20704596.4A patent/EP3917930B1/en active Active
- 2020-01-30 TW TW109102689A patent/TW202045502A/zh unknown
- 2020-01-30 ES ES20704596T patent/ES2941240T3/es active Active
- 2020-01-30 WO PCT/IB2020/050743 patent/WO2020157692A1/en unknown
- 2020-01-30 JP JP2021544518A patent/JP2022523726A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Feighner et al. | Multicenter, placebo-controlled, fixed-dose study of citalopram in moderate-to-severe depression | |
| DK168514B1 (da) | Synergistisk produkt indeholdende en kombination af amantadin og selegilin, fremgangsmåde til fremstilling af produktet og anvendelse af amantadin og selegilin til fremstilling af produktet | |
| ZA200502947B (en) | Use of a combination containing a non-nucleoside reverse transcriptase inhibitor (NNRTI) with an inhibitor of cytochrome P450, such as protease inhibitors | |
| JP5514123B2 (ja) | 卵巣癌を治療するための、パクリタキセルを含む配合剤 | |
| JP2016505561A5 (fi) | ||
| JP2013536837A5 (fi) | ||
| AR073435A1 (es) | Composicion farmaceutica de liberacion modificada de un musculo relajante y un aine | |
| JPWO2020157692A5 (fi) | ||
| JP2024016113A (ja) | ハンチントン病及びその症状を治療するためのプリドピジン及びその類似体を含む組成物 | |
| US20030166696A1 (en) | Pramipexole for the treatment of HIV dementia | |
| CN108078999B (zh) | 用于防治缺血性脑卒中的药物组合物及其制备方法和用途 | |
| UA123780C2 (uk) | Лікування екземи кистей | |
| Pariser et al. | Efficacy and safety of onychomycosis treatments: an evidence-based overview | |
| CA3108739A1 (en) | Treatment of warts | |
| CN108210871A (zh) | 一种治疗疼痛的桂椒姜组合物 | |
| WO2007001058A1 (ja) | ヘルペスウイルス由来疼痛治療剤 | |
| Shahani et al. | Status of chloroquine and hydroxychloroquine in COVID-19 infection | |
| CN117797155B (zh) | 对抗氯胺酮毒性的药物制剂 | |
| JPWO2020254985A5 (fi) | ||
| RU2013141926A (ru) | Терапевтическое применение димирацетама для предотвращения ладонно-подошвенного синдрома, вызываемого сорафенибом | |
| Stevens et al. | (382) Safety and Tolerability of CNTX-4975 in Subjects with Chronic, Moderate to Severe Knee Pain Associated With Osteoarthritis (OA): A Pilot Study | |
| AL IDRISSI et al. | Chloroquineand hydroxychloroquine in covid 19: asystematic review | |
| JPWO2020222108A5 (fi) | ||
| Juan et al. | (381) S3 Transforaminal Epidural Steroid Injections as Treatment of Chronic Testicular Pain | |
| TW202214232A (zh) | 一種組合物的醫藥用途 |